leadf
logo-loader
viewAIM ImmunoTech Inc
(
NYSE:AIM
)

AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2

The study’s authors stated in the peer-reviewed journal Cancers that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19

AIM ImmunoTech Inc - AIM ImmunoTech Inc says its drug Ampligen featured in peer-reviewed medical journal Cancers as potential treatment for cancer patients infected with SARS-CoV-2
AIM was granted a patent by The Netherlands, where Ampligen is being used to treat patients with late-stage pancreatic cancer

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2. 

In a statement, the company said the study’s authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19, which has so far caused more than 3.7 million deaths globally.  

READ: AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus

According to the data presented in the publication, the authors wrote that “Rintatolimod [Ampligen] activated the innate and the adaptive immune systems by activating a cascade of actions in human pancreatic cancer cells,” including:

  • Stimulation of interferon regulatory factors and activation of the interferon signaling pathway;
  • Production of immunomodulatory activity; and
  • Induction of the expression of MHC class I and II histocompatibility.

AIM noted that Cancers is a peer-reviewed, open-access journal of oncology published semi-monthly online by MDPI and the study’s authors include Dr C.H.J. van Eijck, the lead investigator for the Early Access Program at Erasmus Medical Center in The Netherlands, where Ampligen is being used to treat patients with late-stage pancreatic cancer.

“I do think Ampligen fully deserves to be developed for potential approval in the treatment of viral infections, including COVID-19," said Dr van Eijck. "The stimulation of the innate immunity by Ampligen is potentially important in combating aggressive viral infections and could save many lives.”

Additionally, AIM has been granted a patent by The Netherlands. The granted claims include, but are not limited to, the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors (i.e. pembrolizumab and nivolumab). The patent expires December 19, 2039, or 20 years from the date of filing.

“AIM is extremely pleased with the tremendous progress we are making in the Netherlands to advance Ampligen as a therapeutic,” said AIM CEO Thomas Equels. “Prof. van Eijck and his team are preeminent in their field. The data they present is compelling. Also, this patent issuance by the Netherlands is another successful step in our drug development program.”

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: AIM ImmunoTech Inc

Follow
NYSE:AIM

Price: 2.025 USD

Market Cap: $96.89 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

AIM ImmunoTech's Ampligen featured in medical journal Cancers, updates on...

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) CEO Tom Equels talks to Proactive about how its drug Ampligen has been featured in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2. The study’s authors stated that Ampligen...

on 06/22/2021

2 min read